Drugmaker to testify on why weight-loss drugs cost 15x more in the US

US vs. Rest-of-World Pricing

• Many note Ozempic/GLP‑1s are dramatically cheaper in Japan and Canada despite no subsidy, suggesting US prices are not cost-driven.
• Explanations offered:
  • US willingness/ability to pay more (“because we can,” higher incomes, middle/upper-class demand for “cosmetic” drugs).
  • Rich US market allegedly subsidizing poorer countries and price‑controlled systems; others call this narrative propaganda to justify gouging Americans.
  • Some argue the real driver is that US patients/insurers don’t collectively negotiate prices, unlike other countries.

Pharma Economics & R&D

• One side: drugs like Ozempic may cost billions to develop; high US prices are needed to recoup R&D plus many failed projects, in a power‑law “one big hit pays for many misses” model.
• Counterpoints:
  • Back‑of‑envelope math using reported Ozempic sales suggests recouping R&D quickly, even at far lower prices.
  • Studies and political statements cited claiming production cost is a few dollars per month; markup seen as excessive.
  • Debate over how large the “failed drug” multiplier really is (4x vs 10x+), and whether risk is as high as claimed.

US Healthcare Structure & Policy

• Lack of universal/price‑regulated healthcare is seen as a key enabler: access is gated by money, and negotiation power is fragmented.
• Some argue lawmakers created the patent/monopoly framework and could change it (e.g., stronger price controls, public funding, prizes/advance market commitments).
• Others warn that aggressive price controls could undercut innovation globally, given US outsized role in funding biomedical R&D.

Patents, Monopolies, and Fairness

• Patents give time‑limited but powerful monopolies; ideas floated:
  • Expire patents after a profit cap, or add obligations to serve the public good.
  • Governments could buy out blockbuster drugs and make them cheap or generic.
• Tension between shareholder capitalism (“maximize returns”) and societal goals (“necessary medicines shouldn’t be priced like luxury goods”).

Obesity, Behavior, and Public Health

• Some argue the deeper issue is US obesity driven by processed foods, alcohol, and environment; suggest nutrition policy, education, or even bans/taxes.
• Strong pushback against prohibition‑style solutions: mixed historical record, crime and black‑market side effects.
• Ethical debate over how far socialized systems should go in policing behavior to protect collective healthcare budgets.

Markets, Regulation, and Importation

• Basic Econ 101 view: high prices signal high value; controls distort supply and innovation incentives.
• Critics respond that this fails for life‑saving drugs with government‑granted monopolies.
• Noted that arbitrage (buying drugs abroad and reselling in US) is blocked by FDA/legal restrictions; removing these could rapidly compress US prices.